Scientists have found that algae benefit from the better coronavirus drugs
American and Korean scientists have found that heparin, part of the seaweed blocks the new coronavirus is better than ramdevpir is the main drug from COVID-19 used in the United States. The study is published in the journal Cell Discovery.
In order to penetrate into the human cell, the virus SARS-CoV-2 needs to engage his spiculum protein for ACE2 receptor on its surface. But you can send to the virus molecule-the bait similar form, and he will contact her, and then caught in a trap, without possibility of replication, eventually the natural way be destroyed.
American scientists from the Center for biotechnology and interdisciplinary studies, Polytechnic Institute Rensselaer has experienced this method for the neutralization of dengue viruses, Zeke and influenza A. Now, together with colleagues from the Korean research Institute of biological Sciences and biotechnology, they decided to test this approach on the new coronavirus.
"We learn to block viral infection. This knowledge we'll need if we want to resist the pandemics — are in the press release Polytechnic Institute Rensselaer are the words of head of research Jonathan Donica (Jonathan Dordick), Professor of chemical and biological engineering. — The reality is that we have no good antiviral medications. To protect yourself against future pandemics, we will need an Arsenal of approaches that we can quickly adapt to emerging viruses."
By studying the data sequencing SARS-CoV-2, the researchers found several motifs in protein spikes, which promised compatibility with heparin, a known anticoagulant.
The researchers tested the antiviral activity of organic substances extracted from marine algae three variants of heparin and two types of fucoidans. All five compounds are long chain sugar molecules, known as sulfated heteropolysaccharides.
In cell studies, the extract of marine algae for antiviral action far exceeded ramdevpir — modern standard treatment of coronavirus. A major role in the inhibition of infection was carried out with heparin, a widely used blood thinner. The test revealed no cell toxicity none of the compounds even at very high concentrations.
"This is a very complex mechanism, the details of which, we frankly speaking, I don't know, — he says. — In this study, it became clear that the larger the molecule, the better its fit, that is, the more sulfated polysaccharides, which offer a larger number of sites in molecules for capture of the virus, the better the connection."
The authors conducted molecular modeling research-based binding, and identified the areas of the spike protein of the virus, which can interact with heparin.
"We are interested in a new way to fight infection, explains another author Robert Linhardt (Linhardt Robert), Professor of chemistry and chemical biology from the Polytechnic Institute Rensselaer. — Currently, it is believed that infection COVID-19 starts in the nose, and any of these substances could be the basis for the creation of anti-virus nasal spray. It would be a way to treat the infection at an early stage or even prevent it".
Another form of medication for treatment of potential gastrointestinal infections, according to scientists, can become tablets.